These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 8709304)
1. Free-to-total prostate specific antigen ratio as a single test for detection of significant stage T1c prostate cancer. Elgamal AA; Cornillie FJ; Van Poppel HP; Van de Voorde WM; McCabe R; Baert LV J Urol; 1996 Sep; 156(3):1042-7; discussion 1047-9. PubMed ID: 8709304 [TBL] [Abstract][Full Text] [Related]
2. Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial. Southwick PC; Catalona WJ; Partin AW; Slawin KM; Brawer MK; Flanigan RC; Patel A; Richie JP; Walsh PC; Scardino PT; Lange PH; Gasior GH; Parson RE; Loveland KG J Urol; 1999 Oct; 162(4):1346-51. PubMed ID: 10492194 [TBL] [Abstract][Full Text] [Related]
3. Prospective detection of clinically relevant prostate cancer in the prostate specific antigen range 1 to 3 ng./ml. combined with free-to-total ratio 20% or less: the Aarau experience. Recker F; Kwiatkowski MK; Huber A; Stamm B; Lehmann K; Tscholl R J Urol; 2001 Sep; 166(3):851-5. PubMed ID: 11490232 [TBL] [Abstract][Full Text] [Related]
4. Prediction of pathological stage in patients with clinical stage T1c prostate cancer: the new challenge. Veltri RW; Miller MC; Mangold LA; O'Dowd GJ; Epstein JI; Partin AW J Urol; 2002 Jul; 168(1):100-4. PubMed ID: 12050500 [TBL] [Abstract][Full Text] [Related]
5. Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy. Graefen M; Karakiewicz PI; Cagiannos I; Hammerer PG; Haese A; Palisaar J; Huland E; Scardino PT; Kattan MW; Huland H J Urol; 2002 Mar; 167(3):1306-9. PubMed ID: 11832719 [TBL] [Abstract][Full Text] [Related]
6. Standard versus age-specific prostate specific antigen reference ranges among men with clinically localized prostate cancer: A pathological analysis. Partin AW; Criley SR; Subong EN; Zincke H; Walsh PC; Oesterling JE J Urol; 1996 Apr; 155(4):1336-9. PubMed ID: 8632568 [TBL] [Abstract][Full Text] [Related]
7. The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population. Bangma CH; Rietbergen JB; Kranse R; Blijenberg BG; Petterson K; Schröder FH J Urol; 1997 Jun; 157(6):2191-6. PubMed ID: 9146612 [TBL] [Abstract][Full Text] [Related]
8. [A study on parameters to predict tumor volume for stage T1c prostate cancers of Gleason score 6 or less]. Shichiri Y; Egawa S; Kamoto T; Kakehi Y; Ogawa O; Yoshida O; Sumiyoshi Y; Akakura K; Arai Y Hinyokika Kiyo; 2000 Nov; 46(11):785-90. PubMed ID: 11193298 [TBL] [Abstract][Full Text] [Related]
9. Predictors of first repeat biopsy cancer detection with suspected local stage prostate cancer. Fowler JE; Bigler SA; Miles D; Yalkut DA J Urol; 2000 Mar; 163(3):813-8. PubMed ID: 10687983 [TBL] [Abstract][Full Text] [Related]
10. Ratio of free-to-total prostate specific antigen correlates with tumor volume in patients with increased prostate specific antigen. Grossklaus DJ; Shappell SB; Gautam S; Smith JA; Cookson MS J Urol; 2001 Feb; 165(2):455-8. PubMed ID: 11176395 [TBL] [Abstract][Full Text] [Related]
11. Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumors. Jack GS; Cookson MS; Coffey CS; Vader V; Roberts RL; Chang SS; Smith JA; Shappell SB J Urol; 2002 Aug; 168(2):519-24. PubMed ID: 12131301 [TBL] [Abstract][Full Text] [Related]
12. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma. Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461 [TBL] [Abstract][Full Text] [Related]
13. An artificial neural network for prostate cancer staging when serum prostate specific antigen is 10 ng./ml. or less. Zlotta AR; Remzi M; Snow PB; Schulman CC; Marberger M; Djavan B J Urol; 2003 May; 169(5):1724-8. PubMed ID: 12686818 [TBL] [Abstract][Full Text] [Related]
14. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. Brawer MK; Cheli CD; Neaman IE; Goldblatt J; Smith C; Schwartz MK; Bruzek DJ; Morris DL; Sokoll LJ; Chan DW; Yeung KK; Partin AW; Allard WJ J Urol; 2000 May; 163(5):1476-80. PubMed ID: 10751861 [TBL] [Abstract][Full Text] [Related]
15. Clinical usefulness of serum antip53 antibodies for prostate cancer detection: a comparative study with prostate specific antigen parameters. Suzuki H; Akakura K; Igarashi T; Ueda T; Ito H; Watanabe M; Nomura F; Ochiai T; Shimada H J Urol; 2004 Jan; 171(1):182-6. PubMed ID: 14665872 [TBL] [Abstract][Full Text] [Related]
16. Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system. Vashi AR; Wojno KJ; Henricks W; England BA; Vessella RL; Lange PH; Wright GL; Schellhammer PF; Weigand RA; Olson RM; Dowell BL; Borden KK; Oesterling JE Urology; 1997 Jan; 49(1):19-27. PubMed ID: 9000179 [TBL] [Abstract][Full Text] [Related]
17. Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade. Haese A; Vaisanen V; Lilja H; Kattan MW; Rittenhouse HG; Pettersson K; Chan DW; Huland H; Sokoll LJ; Partin AW J Urol; 2005 Mar; 173(3):752-6. PubMed ID: 15711262 [TBL] [Abstract][Full Text] [Related]
18. [Prediction of the stage of patients with prostate cancer by the combination of serum prostate specific antigen and Gleason score]. Song G; Zhou LQ; He ZS; Li NC; Li M; Hao JR; Pan BN; Na YQ Zhonghua Wai Ke Za Zhi; 2006 Mar; 44(6):376-8. PubMed ID: 16638345 [TBL] [Abstract][Full Text] [Related]
19. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range. Haese A; Dworschack RT; Partin AW J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298 [TBL] [Abstract][Full Text] [Related]
20. Multigene methylation analysis for detection and staging of prostate cancer. Enokida H; Shiina H; Urakami S; Igawa M; Ogishima T; Li LC; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R Clin Cancer Res; 2005 Sep; 11(18):6582-8. PubMed ID: 16166436 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]